Abstract: A method of folding a pant-like disposable absorbent garment includes providing a garment defining first and second waist side regions, a waist center region positioned therebetween, and a crotch region longitudinally below the waist center region. In particular embodiments, the method further includes folding the garment along a transversely extending fold line so as to bring the crotch region into superposed relation with the waist center region; providing a chute having a floor and first and second side walls; urging the garment into the chute; and, while the garment is in the chute, folding the garment along longitudinally extending first and second fold lines so as to position the first and second waist side regions over the waist center region. The first and second fold lines are adjacent the first and second side walls, respectively.

Abstract: A method of folding a pant-like disposable absorbent garment includes providing a garment defining first and second waist side regions, a waist center region positioned therebetween, and a crotch region longitudinally below the waist center region. In particular embodiments, the method further includes folding the garment along a transversely extending fold line so as to bring the crotch region into superposed relation with the waist center region; providing a chute having a floor and first and second side walls; urging the garment into the chute; and, while the garment is in the chute, folding the garment along longitudinally extending first and second fold lines so as to position the first and second waist side regions over the waist center region. The first and second fold lines are adjacent the first and second side walls, respectively.

Abstract: A method of folding a pant-like disposable absorbent garment includes providing a garment defining first and second waist side regions, a waist center region positioned therebetween, and a crotch region longitudinally below the waist center region. In particular embodiments, the method further includes folding the garment along a transversely extending fold line so as to bring the crotch region into superposed relation with the waist center region; providing a chute having a floor and first and second side walls; urging the garment into the chute; and, while the garment is in the chute, folding the garment along longitudinally extending first and second fold lines so as to position the first and second waist side regions over the waist center region. The first and second fold lines are adjacent the first and second side walls, respectively.

Abstract: The cryosurgical kit and method of use relates to the combined use of biodegradable, imageable, drug(s) carriers, vectors or microcapsules deposited into a target tissue region inside a body and the controlled cooling of the target tissue region. A minimally invasive method of treatment that applies a cooling device to a selected tissue region, uses a vibrating resonant frequency delivery device to inject drug(s) carriers (microcapsules) containing therapeutic and contrast agents into tissue region(s) submitted to cooling temperatures, successive real-time imaging of the microcapsule deposition and later detection of the progressive degradation of microcapsules with ultrasound imaging which provides estimation of sustained release rates and for planning re-dosing regimens. The thermosensitive microcapsules preferably contain ethiodol, a contrast agent for Ultrasound and/or X-Ray imaging, and cytotoxic drug (s).

Abstract: The cryosurgical kit and method of use relates to the combined use of biodegradable, imageable, drug(s) carriers, vectors or microcapsules deposited into a target tissue region inside a body and the controlled cooling of the target tissue region. A minimally invasive method of treatment that applies a cooling device to a selected tissue region, uses a vibrating resonant frequency delivery device to inject drug(s) carriers (microcapsules) containing therapeutic and contrast agents into tissue region(s) submitted to cooling temperatures, successive real-time imaging of the microcapsule deposition and later detection of the progressive degradation of microcapsules with ultrasound imaging which provides estimation of sustained release rates and for planning re-dosing regimens. The thermosensitive microcapsules preferably contain ethiodol, a contrast agent for Ultrasound and/or X-Ray imaging, and cytotoxic drug (s).

Abstract: The cryosurgical kit and method of use relates to the combined use of biodegradable, imageable, drug(s) carriers, vectors or microcapsules deposited into a target tissue region inside a body and the controlled cooling of the target tissue region. A minimally invasive method of treatment that applies a cooling device to a selected tissue region, uses a vibrating resonant frequency delivery device to inject drug(s) carriers (microcapsules) containing therapeutic and contrast agents into tissue region(s) submitted to cooling temperatures, successive real-time imaging of the microcapsule deposition and later detection of the progressive degradation of microcapsules with ultrasound imaging which provides estimation of sustained release rates and for planning re-dosing regimens. The thermosensitive microcapsules preferably contain ethiodol, a contrast agent for Ultrasound and/or X-Ray imaging, and cytotoxic drug(s).

Abstract: The cryosurgical kit and method of use relates to the combined use of biodegradable, imageable, drug(s) carriers, vectors or microcapsules deposited into a target tissue region inside a body and the controlled cooling of the target tissue region. A minimally invasive method of treatment that applies a cooling device to a selected tissue region, uses a vibrating resonant frequency delivery device to inject drug(s) carriers (microcapsules) containing therapeutic and contrast agents into tissue region(s) submitted to cooling temperatures, successive real-time imaging of the microcapsule deposition and later detection of the progressive degradation of microcapsules with ultrasound imaging which provides estimation of sustained release rates and for planning re-dosing regimens. The thermosensitive microcapsules preferably contain ethiodol, a contrast agent for Ultrasound and/or X-Ray imaging, and cytotoxic drug(s).